Kenneth P Klinker (K P Klinker, Kenneth Klinker)

Years Active: 2018-2022
Publications (10 Years): 5

Merck & Co,Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Merck & Co,Inc Apr 22 2019

United States

Regional Medical Scientific Director :: Merck Research Labs

University of Florida Aug 01 2015 - Apr 19 2019

United States

Clinical Associate Professor :: College of Pharmacy

Publications

Nicole Cossrow, Rennie Joshi, Kenneth P Klinker, Ulrike K Buchwald
Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae . Microorganisms 2022, 10 , 560. Microorganisms 10 (10) (2022)
Mohammad H Alshaer, Michael N Neely, Jiajun Liu, Kartikeya Cherabuddi, Veena Venugopalan, Nathaniel James Rhodes, Kenneth P Klinker, Marc H Scheetz, Charles A Peloquin
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. Antimicrobial agents and chemotherapy 64 (9) (2020)
Cara Nys, Kartik Cherabuddi, Veena Venugopalan, Kenneth P Klinker
Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrobial agents and chemotherapy 63 (11) (2019)
T D Trinh, S C J Jorgensen, E J Zasowski, K C Claeys, A M Lagnf, S J Estrada, D J Delaportes, Vanthida Huang, Kenneth P Klinker, K S Kaye, S L Davis, M J Rybak
Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. Antimicrobial agents and chemotherapy 63 (11) (2019)
Veena Venugopalan, Kayihura Manigaba, Samuel J Borgert, Jessica Cope, Charles A Peloquin, Kenneth P Klinker
Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiology insights 11 (2018)

Kenneth P Klinker.css-eqlu8i{font-size:small;padding-left:4px;} (K P Klinker, Kenneth Klinker)